Finally, chemotherapy (for example, FOLFOX) is known to increase the expression of IL-17A [40], and an IL-17A neutralizing antibody has been shown to enhance the therapeutic responsiveness of established colon tumors [40, 41], which are associated with high MMP-9 activity [42]. The gene discussed is IL17A; the disease is colonic neoplasm.